MEDICAL CORNER
Lead Scientific Examiner
Dr. Professor Katharina Pachmann MD
Bradenburgestrasse 30, D 95448 Bayreuth Germany
Jenaische Str. 7/2 D-07747 Jena
Dr. Pachmann has concentrated her research career on the detection, identification, and treatment of cancer cells in the peripheral blood. Dr. Pachmann has worked in cell research internationally in academically and scientifically acclaimed centres such as Karolinka Insitute Stockholm, Sweden; Institute of Hematology, GSF Munich, Germany; MD Anderson Cancer Centre Houston, Texas.
Presently Dr. Pachmann has her laboratory at the Klinik fur Innere Medizin II Fredrich-Schiller Universitat Jena Germany, where she holds Professorship Experimental Hematology and Oncology. Dr. Pachmann has numerous publications in world renowned journals of Hematology, Clinical Oncology, Surgical Oncology and Cancer Research.
Dr. Pachmann has been requested to present her technology and clinical research at many scientifically and medically respected conferences throughout the America ’s and Europe examples of such are as follows ASCO, ASH, AACR, and American Society of Clinical Oncology's Breast Cancer Symposium and European Society for Medical Oncology.
Dr. Pachmann has developed a technology recognized as Circulating Epithelial Tumour Cell (CETC) testing which detects circulating tumour cells in peripheral blood of patients with cancer. The method involves collecting 1 mL of anticoagulated peripheral blood, which is then processed with an antibody to make epithelial cells fluoresce and run through laser scanning cytometry to count the number of live cells. This cell count provides the oncologist with a baseline prior to initiating treatment, and subsequent CETC testing allows the oncologist to track the therapeutic response to treatment. In addition, monitoring these circulating tumor cells "allows early identification of patients at risk for relapse" and could enable oncologists to modify therapy accordingly.
Dr. Pachmann has also developed a technological technique to expose a patient’s circulating tumour cells to a number of different cytotoxic/ antineoplastic agents (chemotherapy) invitro. Oncologists are able to use the information about cellular responses to the different chemotherapies to individualize and target treatment regimes, and to modify current regimes if the patient’s cancer is not responding to the treatment.
